Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT06552299
Recruiting Not applicable

Evaluating Length and Depth Estimation Accuracy of Laypersons and Health-Care Providers

NCT06552299 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Hospital
Phase
Not applicable
Started
2024-08-27
Last updated
2025-01-17

Condition(s) studied

Cardiopulmonary Resuscitation

Investigational drug(s) / intervention(s)

LaypersonsHealth-Care Providers

Laypersons: 1. Participants will be asked to draw a 5cm line. 2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance.

Health-Care Providers: 1. Participants will be asked to draw a 5cm line. 2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance.

Study summary

The objective of the study is to measure accurateness of length and depth estimation of laypersons and health-care providers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria: * Laypersons: adult laypersons without cardiopulmonary resuscitation training within 2 years * Health-care providers: adult health-care providers (doctors, nurses and emergency medical technicians) Exclusion criteria: * Laypersons: laypersons with cardiopulmonary resuscitation training within 2 years. * Health-care providers: health-care providers who are inactive (not currently working at medical facilities)

Primary outcome measure(s)

  • Depth estimation — Measurement immediately after registration on the day of arrival at the study site (protocol will take less than 5 minutes to complete)
    Depth pressed by participants measured by depth measuring device

Trial sites (1)

FacilityCityRegionStatus
SMG-SNU Boramae Medical Center Seoul South Korea Recruiting

More Seoul National University Hospital trials in South Korea

Lung Cancer Surgery in Sarcopenia Patients With Old Age Active, not recruiting
Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION) Recruiting
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis Recruiting
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer Recruiting
Reduction of Remifentanil-related Complications Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06552299 on ClinicalTrials.gov ↗ ← All trials in South Korea